A5017969033- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Cardiovascular Syncope and Autonomic Disorders
- Pharmaceutical Economics and Policy
- Cardiovascular Function and Risk Factors
- Advanced MRI Techniques and Applications
- Venous Thromboembolism Diagnosis and Management
- Cardiac Ischemia and Reperfusion
- Ion channel regulation and function
- Blood Coagulation and Thrombosis Mechanisms
- Cardiac, Anesthesia and Surgical Outcomes
- Electron Spin Resonance Studies
- Drug Solubulity and Delivery Systems
- Acute Myocardial Infarction Research
- Cardiomyopathy and Myosin Studies
- Statistical Methods in Clinical Trials
- Vascular anomalies and interventions
- Cardiac Arrest and Resuscitation
- Pharmaceutical studies and practices
Linköping University
1990-2022
Linköping University Hospital
2000-2019
Gentofte Hospital
2014-2017
Jönköping University
2016
Rigshospitalet
2014
Örebro University Hospital
2005-2014
Aarhus University Hospital
2014
Tampere University Hospital
2014
Tampere University
2014
University Hospital Leipzig
2014
There are limited data comparing radiofrequency catheter ablation with antiarrhythmic drug therapy as first-line treatment in patients paroxysmal atrial fibrillation.We randomly assigned 294 fibrillation and no history of use to an initial strategy either (146 patients) or class IC III agents (148 patients). Follow-up included 7-day Holter-monitor recording at 3, 6, 12, 18, 24 months. Primary end points were the cumulative per-visit burden (i.e., percentage time on recordings). Analyses...
<h3>Objective</h3> The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial compared radiofrequency catheter ablation (RFA) with antiarrhythmic drug therapy (AAD) as first-line treatment for paroxysmal atrial fibrillation (AF). Endpoint of was elimination electrical activity inside pulmonary veins. We present the results 5-year follow-up. <h3>Methods</h3> This pre-specified follow-up included assessment any AF and symptomatic burden...
The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial assessed the long-term efficacy of an initial strategy radiofrequency ablation (RFA) vs. antiarrhythmic drug therapy (AAD) as first-line treatment for patients with PAF. In this substudy, we evaluated effect these modalities on Health-Related Quality Life (HRQoL) and symptom burden at 12 24 months.During study period, 294 were enrolled MANTRA-PAF randomized to receive AAD (N =...
Aims Elevated levels of C-reactive protein and other inflammatory markers have been reported in some patients with atrial fibrillation (AF). Whether this finding is related to AF per se or conditions remains unclear. In addition, the source unknown. Therefore, present study, we sought assess extent inflammation no concomitant heart conditions.
Nielsen, Jens Cosedis; Johannessen, Arne; Raatikainen, Pekka; Hindricks, Gerhard; Walfridsson, Håkan; Kongstad, Ole; Pehrson, Steen; Englund, Anders; Hartikainen, Juha; Mortensen, Leif Spange; Hansen, Peter Steen Author Information
The aim of this prospective substudy was to estimate the cost-effectiveness treating paroxysmal atrial fibrillation (AF) with radiofrequency catheter ablation (RFA) compared antiarrhythmic drugs (AADs) as first-line treatment.A decision-analytic Markov model, based on MANTRA-PAF (Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation) study data, developed long-term effects and costs RFA AADs treatment. Positive clinical were found overall population, a...
No large randomized multicentre trial has evaluated the efficacy of radiofrequency ablation (RFA) vs. anti-arrhythmic drug (AAD) therapy as a first-line treatment paroxysmal atrial fibrillation (AF).The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation (MANTRA-PAF) is randomized, controlled, parallel group, study designed to test whether catheter-based RFA superior optimized AAD in suppressing relapse within 24 months symptomatic and/or asymptomatic AF patients with without prior...
This randomised trial evaluated if patients with atrial fibrillation (AF) and no history of flutter (AFL) had any benefit prophylactic cavotricuspid isthmus block (CTIB) in addition to circumferential pulmonary vein ablation (CPVA).149 AF (54% paroxysmal) were CPVA CTIB (group CTIB+, n = 73) or alone CTIB-, 76). Patients followed for 12 months repetitive 7-day Holter monitoring after 3, 6 months.Six (4%) cardiac tamponade, one patient a stroke. No difference was found the cumulative AFL-free...
Background There is limited knowledge on the short‐term influence of radiofrequency ablation ( RFA ) atrial fibrillation AF 2 cardiac biomarkers; N‐terminal pro‐B‐type natriuretic peptide NT ‐pro BNP and midregional fragment pro‐ ANP MR extracardiac c‐terminal provasopressin (copeptin) portion proadrenomedullin ADM ). are also data concerning production latter two. Methods Results We studied 192 consecutive patients eligible for referred to University Hospital, Linköping, Sweden. , copeptin,...
Early identification of patients who could benefit from early re-intervention after catheter ablation is highly warranted. Our aim was to investigate the association between post-procedural burden supraventricular ectopic complexes (SVEC) and risk long-term atrial fibrillation (AF) recurrence. A total 125 undergoing for AF were included. Patients underwent 7-day Holter recordings immediately post-procedural. The number SVEC in categorized into quartiles: 0–72, 73–212, 213–782 ≥ 783 SVEC/day....
Abstract Background Primary indication for catheter ablation of atrial fibrillation (AF) is to reduce symptoms and improve health‐related quality life (HRQoL). There are data showing differences between the genders younger older patients. To evaluate this, we studied a large Scandinavian cohort patients referred AF. Methods Consecutive filled out ASTA questionnaire, assessing symptoms, HRQoL, perception arrhythmia, prior ablation. Patients were recruited from four Swedish one Danish tertiary...
The primary goal of radiofrequency ablation (RFA) atrial fibrillation (AF) is to improve symptoms and health-related quality life (HRQoL). However, most studies have focused on predictors AF recurrence rather than improvement in HRQoL.We sought explore arrhythmia-specific HRQoL after RFA AF, evaluate the effects symptoms, HRQoL, anxiety, depression.We studied 192 patients undergoing their first AF. Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), questionnaire tachycardia...
Background Information on alcohol consumption in patients undergoing radiofrequency ablation (RFA) of atrial fibrillation (AF) is often limited by the reliance self-reports. The aim this study was to describe long-term consumption, measured as ethyl glucuronide hair (hEtG), RFA due AF, and examine potential associations with cardiac biomarkers, left size re-ablation within one year after initial RFA. Methods amount hEtG referred for RFA, a cut-off 7 pg/mg used. N-terminal pro B-type...
Introduction Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an estimated prevalence of 1.5–2%. It independent risk factor for ischaemic stroke and to cause about 20–25% all cases. AF has a great impact on health-related quality life (HRQoL); however, one unresolved issue related wide variation in its symptoms. Methods analysis The symptom burden, metabolic profile, ultrasound findings, rhythm, neurohormonal activation, haemodynamics HRQoL patients (Symptom Metabolic...
Biomarker activation in atrial fibrillation (AF) has been widely studied, but the immediate effect of AF initiation remains unclear. We studied on 2 cardiac biomarkers: N-terminal fragment proB-type natriuretic peptide (NT-proBNP), midregional pro-atrial (MR-proANP), and extracardiac biomarkers-the copeptin portion proadrenomedullin (MR-proADM).
Background: Atrial Fibrillation is the most common cardiac arrhythmia.It increases risk of thromboembolic events and many atrial fibrillation patients suffer quality life impairment due to disturbed heart rhythm.Pulmonary vein isolation using radiofrequency catheter ablation treatment aimed at maintaining sinus rhythm ultimately improving life.Randomized clinical trial have shown that more effective than antiarrhythmic drugs for fibrillation, but its impact on cost-effectiveness has not been...
Patients with atrial fibrillation and a DDDR pacemaker were studied to assess mode switching at different sensitivity settings. Thirty-one patients investigated 7 +/- 9 months after implantation 20 of those reinvestigated 23 implant. Adequate was evaluated by stepwise programming the setting from maximal minimal in bipolar mode. observed all 31 during first evaluation. The lowermost average allowing for 1.1 0.7 mV (range 0.3-4.0 mV). A total 22 (71%) demonstrated intermittent shifting...
To determine the best way to detect serious ventricular arrhythmia in patients with hypertrophic Cardiomyopathy (HCMJ, 15 HCM performed an exercise test, had Holter monitoring during 24 hours, and programmed electrical stimulation (PES) a randomized order, presence type of was noted. During testing, only one patient demonstrated tachycardia (VT) just prior test. By monitoring, four short episodes asymptomatic VT. PES, using up three extrastimuli induced VT or fibrillation (VF) ten including...
Background: Some patients continue to have palpitations in spite of successful ablation Wolff‐Parkinson‐White (WPW) syndrome. Recurrence accessory pathways as well unrelated arrhythmias may explain the symptoms. Methods: We followed 194 consecutive after radiofrequency catheter overt (147) or concealed (47) WPW The mean duration symptoms was 16 ±; 13 years. Atrial fibrillation documented 54 (24%) prior ablation. 185 responded a questionnaire 24 12 months Results: physical well‐being improved...